A new PhD studentship, starting in January 2027, has just been announced.
'Mitochondrial Metabolism and Novel Therapeutic Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)' is jointly supervised by the University of Cambridge and Novo Nordisk.
It is an exceptional opportunity to contribute to research addressing one of the world's most pressing metabolic health challenges while receiving world-class training in mitochondrial physiology, translational medicine and drug discovery through a unique partnership between the University of Cambridge and Novo Nordisk.
To find out more, and apply before 25th September 2026, visit the project page.
You can find more about joining the department on our Opportunities at PDN page.
